Filamentous Phages Reduce α-Synuclein Oligomerization in the Membrane Fraction of SH-SY5Y Cells

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 203-205

  Dimant, Hemi ^a   Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Disaggregation; Filamentous phages; Membrane synuclein; SH SY5Y cells

Indexed keywords

ALPHA SYNUCLEIN; BRAIN PROTEIN; OLIGOMER;

CELL AGGREGATION; CONFERENCE PAPER; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CELL MEMBRANE; HUMANS; INOVIRUS; NEUROBLASTOMA; OLIGOPEPTIDES; PROTEIN STRUCTURE, SECONDARY;

EID: 77953553241     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000295664     Document Type: Conference Paper

References (11)

1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
2. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG: The new mutation, E46K, of alpha- synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-173.
3. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
4. Conway KA, Harper JD, Lansbury PT: Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4: 1318-1320.
5. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265-1269.
6. Feany MB, Bender WW: A Drosophila model of Parkinson's disease. Nature 2000; 404: 394-398.
7. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr: Alphasynuclein, especially the Parkinson's disease- associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322: 1089-1102.
8. Lee H-J, Choi C, Lee S-J: Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem 2002; 277: 671-678.
9. Dimant H, Sharon N, Solomon B: Modulation effect of filamentous phage on alphasynuclein aggregation. Biochem Biophys Res Commun 2009; 383: 491-496.
10. El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-425.
11. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D: Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857-868.